Aravive — Investor Presentation (August 2022)
37 slides from Aravive's investor presentation, Aug 26, 2022
Slide 1: Developing Transformative Targeted Cancer Therapeutics
¢3 aravive Developing Transformative Targeted Cancer Therapeutics Corporate Presentation August 2022 NASDAQ: ARAV
Slide 2: Forward Looking Statements
Forward Looking Statements trends, events, results of operations, financial condition or other matters. Forward-looking statements generally include statements that are predictivein nature and depend upon or referto future events or conditions, and they often include words such as “may “would,”“expe
Slide 3: Batiraxcept: A Novel Late-Stage Clinical Program Differentiated from Other Cancer Therapies
Batiraxcept: A Novel Late-Stage Clinical Program Differentiated from Other Cancer Therapies ¢ GASE/AXL signaling drives metastasis and drug resistance but inhibition is challenging. ARAV is the only company targeting GAS6, the activating ligand of AXL Wealth of preclinical studies demonstrate abilit
Slide 4: GAS6 & AXL Expression Associated with Poor Survival in Many Cancers
GAS6 & AXL Expression Associated with Poor Survival in Many Cancers AXL expressed in >70% of ovarian, pancreatic, breast, kidney, and uterine cancers” “Clinically, the expression of GAS6 and TAM receptors always predicts poor prognosis” 3s 6 et MolclorightofGoxeastin ne deepen on ergy et Beth ond Tu
Slide 5: GAS6/AXL Signaling Drives Resistance and Metastasis in Tumors
GAS6/AXL Signaling Drives Resistance and Metastasis in Tumors ‘The GASG/AXL pathway mediates multiple steps of metastasis. + When GAS6, the sole activating ligand, binds toAXL, AXL dimerizes and autophosphorylates its tyrosine residues in the kinase domain. AXL activation regulates downstream signal
Slide 6: Effective Treatment of Human Tumors Requires Drugs that Target Non-metastatic and Metastatic Tumor Cells
Effective Treatment of Human Tumors Requires Drugs that Target Non-metastatic and Metastatic Tumor Cells + Batiraxcept demonstrates single agent activity in preclinical models which have homogeneous, metastatic tumor cells + Human tumors display epitheliakmesenchymal heterogeneity "2° 1x0 ~ Cells wi
Slide 7: GAS6/AXL Signaling: High Affinity Decoy Receptor is the Best Approach
GAS6/AXL Signaling: High Affinity Decoy Receptor is the Best Approach for Potent and Selective Inhibition Tyrosine Kinase Inhibitor AXL or GAS6 Antibody dhol + Soloctvty limited by RTK homology + Requires @ mAB affinty that competes + Binds more tighty to GASS than WT AXL + Oftarget toxicity ee + Co
Slide 8: Batiraxcept (AVB-500): High Affinity, Highly Specific GAS6/AXL Inhibitor
Batiraxcept (AVB-500): High Affinity, Highly Specific GAS6/AXL Inhibitor Modified AXL-Fc fusion protein engineered for strong stability and very high affinity for GAS6 + ~200 fold greater affinity for human GAS6 compared to native AXL receptor + Preclinical data demonstrated relationship between aff
Slide 9: Experienced Management and Board of Directors
Experienced Management and Board of Directors SENIOR MANAGEMENT 2A ExecChaiman cf the Board ceo cro ete akan eee stad PL ORBT SOR LPRD. inl HoOCrACPA. Ronan thor MD, BOARD OF DIRECTORS 2020008" nae Choman ofthe Board Draco rata Ovecee rector Draco race rector Fredtaainn, ham. Amato GlosiePh0. Peri,
Slide 10: Aravive Pipeline
Aravive Pipeline Opportunity for Expansion into Additional Indications and Drug Combinations Indication Preclinical Phase 1 Phase 2 Phase 3 Batiraxcept (AVB-500) OVARIAN CANCER (botrarcep»pactaxe) CLEAR CELL RENALCANCER te Line (btrarcept scaboranind + re eaaxcept + cabo 1 inlgaie for curate tert he
Slide 11: Batiraxcept May Unlock ~$2.6B in Global Revenue Across PROC, Renal and Pancreatic Tumors
Batiraxcept May Unlock ~$2.6B in Global Revenue Across PROC, Renal and Pancreatic Tumors, with PROC Representing a Near-term Growth Driver Potential for Large Total Accessible Market Across Multiple Tumor Types Marketing Estimates / Indication PROC (bevacizumab naive) = PROC (bevacizumab experienced
Slide 12: Batiraxcept: Platinum-Resistant Ovarian Cancer (PROC)
Batiraxcept: Platinum-Resistant Ovarian Cancer (PROC)
Slide 13: Summary of Phase 1a Healthy Volunteer and 1b PROC Studies
Summary of Phase 1a Healthy Volunteer and 1b PROC Studies Phase 1a single ascending dose and repeat dose study in healthy volunteers + 43 subjects participated; 42 dosed + Batiraxcept was welltolerated across doses of 1-10 mg/kg Batiraxcept; no SAEs + No anti-drug antibodies (ADA) + 10 mg/kg (iV) ad
Slide 14: Batiraxcept + Paclitaxel Clinical Activity Associated with Exposure
Batiraxcept + Paclitaxel Clinical Activity Associated with Exposure Modeling Identified RP2D of 15 mg/kg + Traditional MTD or DLT approach for identification of RP2D not appropriate for batiraxcept due to its benign safety profile + Exposure-response relationship identified by unsupervised ‘computer
Slide 15: Exposure-Response Modeling Consistent with Preclinical Data
Exposure-Response Modeling Consistent with Preclinical Data + Exposure-Response modeling of P1b PROC and P1b ccRCC demonstrates a plateau at 20mg/kg + Preclinical data from ovarian cancer model demonstrated plateau from 10 to 20mg/kg (equateto ! lower doses in humans) — No toxicity issues identified
Slide 16: Time on Treatment and Depth of Response for Batiraxcept + Paclitaxel Patients
Time on Treatment and Depth of Response for Batiraxcept + Paclitaxel Patients (10 and 15 mg/kg groups) 96% were on 3"+ Line of Therapy; Literature Demonstrates 85% of Patients on their 34 Line of Therapy have Progressive Disease by their First CT Scan’ PFs Month frParetcl 10 mah and 15 ma/ng AVBSOO$
Slide 17: Evidence of Monotherapy
Evidence of Monotherapy PROC 1B: batiraxcept monotherapy (15mg/kg) maintained complete response in 1 patient for 8 months and batiraxcept monotherapy (10mg/kg) maintained partial responses for 5 months in 2 patients following PAC and PLD and this is consistentwith mechanism of action PAC = panel PLO
Slide 18: Promising Responses in Patients in Later Lines of Therapy
Promising Responses in Patients in Later Lines of Therapy and <3 Month Platinum-Free Interval Compared to Literature Invasive Tumors Resistant to Multiple Lines of Therapy Expected to Be Dependent on the GAS6/AXL Pathway CLINICALRESPONSE CLINICALRESPONSE OF BATIRAXCEPT+ CHEMO'INPATIENTS ‘OF CHEMOTHE
Slide 19: Batiraxcept Phase 3 Registrational Trial Design in PROC
Batiraxcept Phase 3 Registrational Trial Design in PROC (ClinicalTrials.gov NCT04729608) + FDA Feedback: If positive, trial could support full approval in PROC; no further preciinical or clinical studies required for BLA at this time + Endpoint Assessment: PFS per RECIST V1.1; radiological imaging e
Slide 20: Market Research Suggests Batiraxcept Would Fill an Unmet Need in PROC
Market Research Suggests Batiraxcept Would Fill an Unmet Need and Be Adopted into the Current PROC Treatment Paradigm “Platinumresistantpatients are in needofnewtargetedtreatment options." Healthcare Provider “To seethis levelof safety with the improved efficacy is impressive—| certainly woulduse th
Slide 21: Batiraxcept: Clear Cell Renal Cell Carcinoma (ccRCC)
Batiraxcept: Clear Cell Renal Cell Carcinoma (ccRCC)
Slide 22: Batiraxcept + Cabozantinib Phase 1b/2 Trial Design in ccRCC
Batiraxcept + Cabozantinib Phase 1b/2 Trial Design in ccRCC (NCT04300140) Populatior ‘+ 26 patients (P1b) and 55 patients Phase tb oer (P2; currently enrolling) 1 oe * Histtogialy confirmed metastatic ’ ‘At east rior line of therapy (N=25) ceRCC and progressed on/after a - a aera front-line treatmen
Slide 23: P1b ccRCC Study: Safety Profile Consistent with Cabozantinib
P1b ccRCC Study: Safety Profile Consistent with the Established Safety Profile for Cabozantinib 45 mgikg Pb 20 mgikg Pb Safety oe Patients Pationts (N= 46) (N=10) Batiraxcept-Related Deaths 0 0 0 Grade 3 Adverse Events (AES), 5 (19.2%) 3 (18.8%) 2 (20%) related to Batiraxcept Events: HTN Events: HTN
Slide 24: P1b ccRCC: Clinical Activity of Batiraxcept + Cabozantinib
P1b ccRCC: Clinical Activity of Batiraxcept + Cabozantinib nee eae All tb Patnts Pib 15 mola PAb 20 mg/kg Best Response Confirmed Partial Response 11 (42%) 8 (60%) 3 (30%) Confirmed Stable Disease 11 (42%) 6 (38%) 5 (50%) Progressive Disease 4 (15%) 2 (12%) 2 (20%) 9-month Progression-Free 65% 61% 7
Slide 25: P1b ccRCC: Pretreatment Serum sAXL/GAS6 Biomarker
P1b ccRCC: Pretreatment Serum sAXL/GAS6 Biomarker with 100% Negative Predictability Best Response AllP1b Patients P1b15mg/kg Pb 20 mg/kg (n=25) * (n=16) (n=9) * PR for Patients with low sAXL/GAS6 0/5 (0%) 0/4 (0%) O/1 (0%) Confirmed PR for Patients with high 11/20 (55%) 8/12 (67%) 2 3/8 (38%) ‘SAXLI
Slide 26: Batiraxcept Registrational Trial Design in ccRCC
Batiraxcept Phase 3 Registrational Trial Design in ccRCC + FDA Recommendation: Integrated P2/3 study with interim analyses to look at futlity in the biomarker low population and ORR for potential accelerated approval with PFS endpoint for full approval. Full protocol and statistical plan in preparat
Slide 27: Market Research Suggests Batiraxcept Would Fill an Unmet Need in ccRCC
Market Research Suggests Batiraxcept Would Fill an Unmet Need and Be Adopted into the Current ccRCC Treatment Paradigm The upside efficacy wouldbe practice- ‘changing in2L...| would offert to mostof the biomarkerpositive population, "— KOL Improved2L Improved efficacy over cabozantinio was seen as p
Slide 28: Batiraxcept: Pancreatic Adenocarcinoma
Batiraxcept: Pancreatic Adenocarcinoma
Slide 29: Batiraxcept + Gemcitabine + nab-Paclitaxel Phase 1b/2 Trial Design in 1L PDAC
Batiraxcept + Gemcitabine + nab-Paclitaxel Phase 1b/2 Trial Design in 1L Pancreatic Adenocarcinoma (NCT04983407) P1b Population: + Patients (N~20) with advanced or metastatic pancreatic adenocarcinoma eligible to receive gemcitabine + nab- paclitaxel (Abraxane®) as first-line treatment Phase 1b Phas
Slide 30: Safety Profile Consistent with Gemcitabine + nab-Paclitaxel in P1b PDAC
Safety Profile Consistent with the Established Safety Profile for Gemcitabine + nab Paclitaxel or Underlying Disease In P1b PDAC Study All P1b Patients 15 mg/kg Batiraxcept + Gemcitabine+ nab- Paclitaxel (N= 21) Batiraxcept-Related Deaths ) Grade 3 Adverse Events (AEs), related to 6 (29%) Batiraxcep
Slide 31: Initial Anti-Tumor Activity from Phase 1b PDAC Trial
Initial Anti-Tumor Activity from Phase 1b PDAC Trial: 15 mg/kg Batiraxcept + Gemcitabine+ nab-Paclitaxel Best Response All P1b Patients (N= 21) Confirmed Partial Response 6 (29%) Stable Disease 5 (24%) Progressive Disease 5 (24%) Not Evaluable 3 (14%) Not Applicable (died before any post-baseline sc
Slide 32: P1b PDAC: Pretreatment Serum sAXL/GAS6 is a Potential Biomarker
P1b PDAC: Pretreatment Serum sAXL/GASG is a Potential Biomarker All P1b Patients 15 mg/kg Batiraxcept + Gemcitabine+ nab- Paclitaxel (N= 21) 016 (0%) 6/15 (40%) PR for Patients with low sAXL/GAS6 Confirmed PR for Patients with high sAXL/GAS6 + Exact biomarker threshold to be determined once all data
Slide 33: Market Research Suggests Batiraxcept Would Fill an Unmet Need in PDAC
Market Research Suggests Batiraxcept Would Fill an Unmet Need and Be Adopted into the Current PDAC Treatment Paradigm Note: physicians’ comments basedon Pib data 2
Slide 34: Upcoming Key Milestones
Upcoming Key Milestones P3 PROC Top Line Results Potential Approval of Updated P1b PDAC Data i —- — Submit BLA for PROC, if PROC BLA fety and Preliminary trial successful — coy vom P2ceRC Tra Monel P2ceRCC Tal fia Data, Safety and Preliminary Complete Enrolment of 3 tat Initiate P2 PDAC Trialt Activ
Slide 35: Financial Summary
Financial Summary $46.8 30.5 Million* No Debt Cash Runway Million* Shares Expected to Fund Cash and Cash Outstanding Base Operating Equivalents Plan into Q1 2023
Slide 36: Dedicated to Developing Innovative Treatments for Life-Threatening Diseases
Dedicated to Developing Innovative Treatments for Life-Threatening Diseases to Increase Patient Survival Batiraxcept development program focused on difficult-to-treat cancers with high unmet medical needs Proprietary, differentiated first-in-class therapeutic targeting and inhibiting GASG/AXL signal
Slide 37: Thank you
¢3 aravive Thank you Corporate Presentation August 2022 NASDAQ: ARAV